First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $1.2B — +9.3% growth in a single year.
What Moves the Stock
1Organic revenue growth rates in core brands (particularly Dramamine, Monistat, Clear Eyes) which signal brand health and market share trends
2M&A announcements and integration execution - acquisitions typically drive 12-18 month stock rallies when accretive deals are announced at reasonable multiples
3Gross margin trajectory reflecting input cost pressures (packaging, freight, raw materials) versus pricing actions and product mix shifts
4Free cash flow generation and capital allocation decisions including debt paydown, share repurchases, and dividend policy
5Retailer inventory destocking or restocking cycles which create quarterly volatility in shipment patterns versus consumption trends
6North American OTC healthcare brands (~95% of revenue) sold through retail channels including mass merchandisers, drug stores, and e-commerce
7International sales (~5% of revenue) primarily in Canada, Australia, and select export markets
8Portfolio spans digestive health, women's health, eye/ear care, and dermatology with no single brand exceeding 15% of total revenue
value/dividend - The stock appeals to value investors seeking defensive cash flow generators trading at reasonable multiples (12.4x…
Rising rates create moderate headwinds through two channels: (1) increased interest expense on $600M+ debt load (mix of fixed and floating…
Watch on earnings: Nielsen/IRI consumption data for top 10 brands showing unit velocity and market share trends versus shipment data, Gross margin progression reflecting input cost inflation (CPIAUCSL) versus pricing realization and product mix, Retailer inventory levels in weeks-of-supply to identify destocking or restocking cycles affecting quarterly shipments.
One Sentence Summary:
Prestige Consumer Healthcare: the story is balanced — organic revenue growth rates in core brands (particularly dramamine, monistat, clear eyes) which signal brand health and market share trends.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.